Oncopeptides (Q3 Initial take): Sequential Growth of 5% - Redeye
Redeye provides its first take on Oncopeptides' Q3 report 2025. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Overall, the quarter was somewhat below our expectations.
ANNONS
Redeye provides its first take on Oncopeptides' Q3 report 2025. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Overall, the quarter was somewhat below our expectations.
